Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Upregulation of TSPAN12 is associated with the colorectal cancer growth and metastasis.

Liu J, Chen C, Li G, Chen D, Zhou Q.

Am J Transl Res. 2017 Feb 15;9(2):812-822. eCollection 2017.

2.

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.

Chua MM, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, Dominguez I.

Pharmaceuticals (Basel). 2017 Jan 28;10(1). pii: E18. doi: 10.3390/ph10010018. Review.

3.

Human BCDIN3D monomethylates cytoplasmic histidine transfer RNA.

Martinez A, Yamashita S, Nagaike T, Sakaguchi Y, Suzuki T, Tomita K.

Nucleic Acids Res. 2017 May 19;45(9):5423-5436. doi: 10.1093/nar/gkx051.

4.

Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients.

Wu J, Zhou L, Huang L, Gu J, Li S, Liu B, Feng J, Zhou Y.

J Exp Clin Cancer Res. 2017 Jan 5;36(1):4. doi: 10.1186/s13046-016-0477-x.

5.

Transcriptional Network Architecture of Breast Cancer Molecular Subtypes.

de Anda-Jáuregui G, Velázquez-Caldelas TE, Espinal-Enríquez J, Hernández-Lemus E.

Front Physiol. 2016 Nov 22;7:568. eCollection 2016.

6.

CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT.

Chaudhury A, Cheema S, Fachini JM, Kongchan N, Lu G, Simon LM, Wang T, Mao S, Rosen DG, Ittmann MM, Hilsenbeck SG, Shaw CA, Neilson JR.

Nat Commun. 2016 Nov 21;7:13362. doi: 10.1038/ncomms13362.

7.

miR-139-5p regulates proliferation, apoptosis, and cell cycle of uterine leiomyoma cells by targeting TPD52.

Chen H, Xu H, Meng YG, Zhang Y, Chen JY, Wei XN.

Onco Targets Ther. 2016 Oct 11;9:6151-6160. eCollection 2016.

8.

Simultaneous Proteomic Discovery and Targeted Monitoring using Liquid Chromatography, Ion Mobility Spectrometry, and Mass Spectrometry.

Burnum-Johnson KE, Nie S, Casey CP, Monroe ME, Orton DJ, Ibrahim YM, Gritsenko MA, Clauss TR, Shukla AK, Moore RJ, Purvine SO, Shi T, Qian W, Liu T, Baker ES, Smith RD.

Mol Cell Proteomics. 2016 Dec;15(12):3694-3705. Epub 2016 Sep 25.

PMID:
27670688
9.

Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.

Mihály Z, Győrffy B.

Microarrays (Basel). 2013 Aug 29;2(3):228-42. doi: 10.3390/microarrays2030228. Review.

10.

Genotypes of cancer stem cells characterized by epithelial-to-mesenchymal transition and proliferation related functions.

Hsu CL, Chung FH, Chen CH, Hsu TT, Liu SM, Chung DS, Hsu YF, Chen CL, Ma N, Lee HC.

Sci Rep. 2016 Sep 6;6:32523. doi: 10.1038/srep32523.

11.

The hedgehog pathway in triple-negative breast cancer.

Habib JG, O'Shaughnessy JA.

Cancer Med. 2016 Oct;5(10):2989-3006. doi: 10.1002/cam4.833. Epub 2016 Aug 18. Review.

12.

KRT19 directly interacts with β-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties.

Saha SK, Choi HY, Kim BW, Dayem AA, Yang GM, Kim KS, Yin YF, Cho SG.

Oncogene. 2017 Jan 19;36(3):332-349. doi: 10.1038/onc.2016.221. Epub 2016 Jun 27.

13.

Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance.

AlHossiny M, Luo L, Frazier WR, Steiner N, Gusev Y, Kallakury B, Glasgow E, Creswell K, Madhavan S, Kumar R, Upadhyay G.

Cancer Res. 2016 Jun 1;76(11):3376-86. doi: 10.1158/0008-5472.CAN-15-2654. Epub 2016 Apr 11.

14.

Breast cancer stem-like cells: clinical implications and therapeutic strategies.

Tudoran OM, Balacescu O, Berindan-Neagoe I.

Clujul Med. 2016;89(2):193-8. doi: 10.15386/cjmed-559. Epub 2016 Apr 15. Review.

15.

FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.

Pietilä M, Vijay GV, Soundararajan R, Yu X, Symmans WF, Sphyris N, Mani SA.

Sci Rep. 2016 Apr 11;6:23070. doi: 10.1038/srep23070.

16.

The NF-κB Pathway and Cancer Stem Cells.

Rinkenbaugh AL, Baldwin AS.

Cells. 2016 Apr 6;5(2). pii: E16. doi: 10.3390/cells5020016. Review.

17.

Monitoring cancer stem cells: insights into clinical oncology.

Lin S, Xu Y, Gan Z, Han K, Hu H, Yao Y, Huang M, Min D.

Onco Targets Ther. 2016 Feb 11;9:731-40. doi: 10.2147/OTT.S96645. eCollection 2016.

18.

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Laas E, Mallon P, Duhoux FP, Hamidouche A, Rouzier R, Reyal F.

PLoS One. 2016 Feb 19;11(2):e0148957. doi: 10.1371/journal.pone.0148957. eCollection 2016.

19.

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.

N Engl J Med. 2016 Jan 21;374(3):211-22. doi: 10.1056/NEJMoa1506597.

20.

Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1.

Xu Y, Xu S, Cai Y, Liu L.

Evid Based Complement Alternat Med. 2015;2015:145016. doi: 10.1155/2015/145016. Epub 2015 Dec 13.

Supplemental Content

Support Center